UK private equity firm Maven Capital Partners has realised its investment in the scientific instrument developer Blacktrace Group with a strategic sale to US life science tools corporate Unchained Labs.
The sale represents Maven’s third profitable exit in 2023, having earlier in the year sold Hedgehog Lab, a mobile app and web development specialist, and Titan Wealth, a consolidator in the discretionary fund management sector.
The deal is the second profitable sale from the Blacktrace Group following the acquisition of the Group’s Syrris unit by Japanese corporate Asahi Glassplant in early 2020.
Maven clients invested in Blacktrace in 2016. Blacktrace sells its scientific products, based on its unrivalled microfluidics expertise and technology into a range of international markets via leading brands including Dolomite Microfluidics, Dolomite Bio and Particle Works.
Backed by global investment firm Carlyle, Unchained Labs is a life sciences tools company focused on solving problems for biologics and gene therapy researchers.
